Innova CaptabQ4 FY24

Innova Captab Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,037.7P/E: 35.6Market Cap: ₹5.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • The company expects a strong growth in CDMO business, targeting 20%+ CAGR in the coming year, driven by new capacity from Jammu facility and increased utilization of existing facilities.
  • Volume growth in CDMO is projected at 10%+ annually; revenue growth depends on price stability or increase.
  • With the Jammu facility coming online, acute segment sales are expected to increase, boosting overall revenue.
  • Gross margins expected to stabilize around 25%-26%, with improved margins from Jammu due to GST benefits.
  • EBITDA growth is linked to volume growth rather than top-line revenue, with a 10% increase in standalone EBITDA reported.
  • Export business and branded generics are also focused growth areas alongside CDMO.
  • New inquiries and customer onboarding for Jammu facility are in advanced stages, expected to convert into revenue within 4-5 months post commercial production start.

See what Innova Captab management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • No specific mention of new fundraising through debt or equity in the current call.
  • The company has repaid all existing debt excluding the term loan for the Jammu project.
  • The Jammu project is funded partly by a Rs. 235 crore project loan at 6% interest subvention.
  • IPO proceeds of Rs. 293 crores are being deployed as planned over two years; about Rs. 62 crores planned for FY25.
  • No indication of fresh equity or debt raising beyond the existing Jammu project loan and IPO proceeds utilization.
  • Capex plans include another Rs. 100 crore investment in the Jammu facility during the year.
  • Overall, the company appears focused on utilizing current resources and existing loans rather than new fundraising.

See what Innova Captab management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Ongoing capital work in progress is primarily for the Jammu project, with around Rs. 330 crore invested so far.
  • Total anticipated project cost for Jammu facility is approximately Rs. 450 crore, with an expected additional Rs. 100 crore investment in coming quarters.
  • Commercial production at Jammu is planned to start in Q2 FY25.
  • Normal maintenance CAPEX for existing operations is estimated around Rs. 5-7 crores per annum.
  • Future investments aim to enhance capacity, including three more blocks at Jammu and expansion of Cephalosporin block.
  • The company expects to utilize IPO proceeds as planned and has repaid all existing debt except the project loan for Jammu.
  • Jammu facility benefits from GST and interest subvention incentives expected to improve margin profile.

Track Innova Captab — get its next earnings analysis in your feed

How does Innova Captab rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisInnova Captab
Rev 2Mar 2

How does Innova Captab rank in Pharmaceuticals & Biotechnology?

Compare Innova Captab against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →